Fig. 3From: Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysisNetwork plot for MACE. SGLT-2 sodium-glucose cotransporter 2, GLP-1 RA glucagon-like peptide-1 receptor agonist, MACE major adverse cardiovascular eventsBack to article page